Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

3D Printing in Rheumatology Holds Promise for External Devices, Joints

3D Printing in Rheumatology Holds Promise for External Devices, Joints

Bryn Nelson, PhD  |  July 11, 2016

When Abby Paterson, PhD, started her doctoral work in product design and technology at Loughborough University in the United Kingdom in 2009, she says 3D printing was little known by clinicians or the general public. Now, the technology is seemingly everywhere. For Dr. Paterson, the advancing science has led to a promising project focused on…

Filed under:Technology Tagged with:jointspatient carerheumatologyTechnology

Rheumatology Case Report: Concomitant Lupus with Features of Scleroderma, Castleman Disease

Kwabna Parker, MBBS, Sireesha Datla, MD, & Nancy Soloman, MD  |  July 11, 2016

We report a case of a 27-year-old woman who was initially diagnosed with systemic lupus erythematosus (SLE), had features of scleroderma and was subsequently found to have lymph node biopsy consistent with multicentric Castleman disease (MCD). She also had serologic evidence of acute Epstein-Barr virus (EBV) infection (vs. reactivation of EBV). The occurrence of MCD…

Filed under:ConditionsSystemic Sclerosis Tagged with:Castleman's diseaseClinicalLupusoutcomepatient carerheumatologySclerodermaSLE

Why Rheumatologists Should Focus on Patients’ Cardiovascular Health

Simon M. Helfgott, MD  |  July 10, 2016

Baseball is a great sport. It’s fascinating to watch the evolving duel between pitcher and batter. As the former employs their remarkably powerful and versatile rotator cuff and forearm flexor muscles to hurl blazing pitches, the latter engages their exceptionally honed hand–eye neural link to make contact with the ball. Baseball is the ultimate summertime…

Filed under:OpinionPractice SupportRheuminationsSpeak Out Rheum Tagged with:cardiovascularhypertensionmetabolic syndromeObesitypatient carePractice ManagementRheumatic Diseaserheumatologist

From the Expert: Enhance Your Teachable Moments to Attract Residents to Rheumatology

Richard Quinn  |  July 8, 2016

Attracting medical residents to rheumatology has been difficult. However, Eli Miloslavsky, MD, believes enhancing the teaching skills of rheumatology fellows, enabling them to push through barriers on the ward and leverage teachable moments with residents, may improve patient care and influence a resident’s choice of subspecialty…

Filed under:Education & Training Tagged with:Clinical PracticeEducationfellowshipinternal medicineTraining

Medicare Advantage Grows, but Provider Choice Is Limited

Mark Miller  |  July 7, 2016

CHICAGO (Reuters)—Medicare enrollees are moving in greater numbers than ever to the program’s managed care option as a way to save money. But the tradeoff is much less ability to use their preferred doctors and hospitals. Seniors can choose between traditional fee-for-service Medicare—which is accepted by most healthcare providers—or a Medicare Advantage plan. The latter…

Filed under:Legislation & AdvocacyProfessional Topics

Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2016

In a recent study, 100% of patients with rheumatoid arthritis (RA) on infliximab experienced a cross-reaction when switched to its biosimilar (CT-P13, infliximab-dyyb). Plus in a recent study, a treat-to-target strategy proved effective for treating RA with biological disease-modifying anti-rheumatic drugs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBiologicsBiosimilarsDisease-modifying antirheumatic drugs (DMARDs)infliximabinfliximab-dyybRheumatoid Arthritis (RA)

Periodontal Infection May Determine Best Treatment for Patients with RA

Lara C. Pullen, PhD  |  July 4, 2016

Past research has indicated that a periodontal pathogen that produces the peptidularginine deiminase (PPAD) enzyme may affect levels of anti-cyclic citrullinated peptide antibody. A new study suggests serum anti-PPAD IgG titers might be a useful biomarker for designing a personalized treatment strategy for RA…

Filed under:ConditionsRheumatoid Arthritis Tagged with:BiologicsDisease-modifying antirheumatic drugs (DMARDs)InfectionPeriodontal diseaseRheumatoid Arthritis (RA)

Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA

Michele B. Kaufman, PharmD, BCGP  |  June 29, 2016

A recent study found that certolizumab pegol plus methotrexate is effective in achieving sustained remission and low disease activity in patients with early active RA…

Filed under:Drug Updates Tagged with:Certolizumab Pegolcombination therapyDisease-modifying antirheumatic drugs (DMARDs)Methotrexate

Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

Michele B. Kaufman, PharmD, BCGP  |  June 22, 2016

The FDA is currently accepting comments on a draft guideline for osteoporosis treatments, which calls for more research into the long-term effects of drugs on bone quality. Also, the FDA has rejected an application for approval of Apadaz in its current form…

Filed under:AnalgesicsConditionsDrug UpdatesOsteoarthritis and Bone DisordersPain Syndromes Tagged with:Benzhydrocodone hydrochlorideChronic painFDAFood and Drug AdministrationGuidelinesOsteoporosispostmenopauseRegulation

Doctors Blame Many Factors for Futile Care, Themselves Included

Randi Belisomo  |  June 20, 2016

(Reuters Health)—Doctors who were asked about causes of inappropriate care at the end of life didn’t have to look far to place blame. They blamed themselves. Australian researchers interviewed 96 physicians from 10 medical specialties and asked them to describe situations when patients received end of life care that the doctors felt was inappropriate. Futile…

Filed under:ConditionsPractice Support Tagged with:end-of-lifefutile medical treatmentmortalitypatient carephysician

  • « Previous Page
  • 1
  • …
  • 208
  • 209
  • 210
  • 211
  • 212
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences